These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 25173564)
41. Intrathecal drug administration in chronic pain syndromes. Ver Donck A; Vranken JH; Puylaert M; Hayek S; Mekhail N; Van Zundert J Pain Pract; 2014 Jun; 14(5):461-76. PubMed ID: 24118774 [TBL] [Abstract][Full Text] [Related]
42. Ease of Fill Port Access During the Ultrasound-Guided vs. the Blind Refill Technique of Intrathecal Drug Delivery Systems With a Raised Septum, a Prospective Comparison Study. Maino P; van Kuijk SMJ; Perez RSGM; Koetsier E Neuromodulation; 2018 Oct; 21(7):641-647. PubMed ID: 29206310 [TBL] [Abstract][Full Text] [Related]
43. Pancreatic Cancer Related Pain: Review of Pathophysiology and Intrathecal Drug Delivery Systems for Pain Management. Carvajal G Pain Physician; 2021 Aug; 24(5):E583-E594. PubMed ID: 34323445 [TBL] [Abstract][Full Text] [Related]
44. Patient selection and outcomes using a low-dose intrathecal opioid trialing method for chronic nonmalignant pain. Grider JS; Harned ME; Etscheidt MA Pain Physician; 2011; 14(4):343-51. PubMed ID: 21785477 [TBL] [Abstract][Full Text] [Related]
45. Intrathecal Drug Delivery Systems for Cancer Pain: An Analysis of a Prospective, Multicenter Product Surveillance Registry. Stearns LM; Abd-Elsayed A; Perruchoud C; Spencer R; Hammond K; Stromberg K; Weaver T Anesth Analg; 2020 Feb; 130(2):289-297. PubMed ID: 31567325 [TBL] [Abstract][Full Text] [Related]
47. A Contemporary Medicolegal Analysis of Implanted Devices for Chronic Pain Management. Abrecht CR; Greenberg P; Song E; Urman RD; Rathmell JP Anesth Analg; 2017 Apr; 124(4):1304-1310. PubMed ID: 28319551 [TBL] [Abstract][Full Text] [Related]
48. Use of eptifibatide as a bridge antiplatelet agent for intrathecal drug delivery system placement. Sisk J; Palma M; Cooper C; Eltahawy E; Atallah J Pain Physician; 2012; 15(6):479-83. PubMed ID: 23159964 [TBL] [Abstract][Full Text] [Related]
49. Intrathecal Gadolinium Use for the Chronic Pain Physician. Hagedorn JM; Bendel MA; Moeschler SM; Lamer TJ; Pope JE; Deer TR Neuromodulation; 2019 Oct; 22(7):769-774. PubMed ID: 31448498 [TBL] [Abstract][Full Text] [Related]
50. Intrathecal pain pumps: indications, patient selection, techniques, and outcomes. Bolash R; Mekhail N Neurosurg Clin N Am; 2014 Oct; 25(4):735-42. PubMed ID: 25240660 [TBL] [Abstract][Full Text] [Related]
51. History and present state of targeted intrathecal drug delivery. Rizvi S; Kumar K Curr Pain Headache Rep; 2015; 19(2):474. PubMed ID: 25638694 [TBL] [Abstract][Full Text] [Related]
52. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. Smith TJ; Staats PS; Deer T; Stearns LJ; Rauck RL; Boortz-Marx RL; Buchser E; CatalĂ E; Bryce DA; Coyne PJ; Pool GE; J Clin Oncol; 2002 Oct; 20(19):4040-9. PubMed ID: 12351602 [TBL] [Abstract][Full Text] [Related]
53. Intrathecal Drug Delivery Systems (IDDS): The Implantable Systems Performance Registry (ISPR). Konrad PE; Huffman JM; Stearns LM; Plunkett RJ; Grigsby EJ; Stromberg EK; Roediger MP; Wells MD; Weaver TW Neuromodulation; 2016 Dec; 19(8):848-856. PubMed ID: 27730704 [TBL] [Abstract][Full Text] [Related]
55. Multimodal intrathecal analgesia in refractory cancer pain. Mastenbroek TC; Kramp-Hendriks BJ; Kallewaard JW; Vonk JM Scand J Pain; 2017 Jan; 14():39-43. PubMed ID: 28850428 [TBL] [Abstract][Full Text] [Related]
56. An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM). Smith TJ; Coyne PJ; Staats PS; Deer T; Stearns LJ; Rauck RL; Boortz-Marx RL; Buchser E; CatalĂ E; Bryce DA; Cousins M; Pool GE Ann Oncol; 2005 May; 16(5):825-33. PubMed ID: 15817596 [TBL] [Abstract][Full Text] [Related]
57. Bleeding Complications in Patients Undergoing Intrathecal Drug Delivery System Implantation. Warner NS; Bendel MA; Warner MA; Strand JJ; Gazelka HM; Hoelzer BC; Mauck WD; Lamer TJ; Kor DJ; Moeschler SM Pain Med; 2017 Dec; 18(12):2422-2427. PubMed ID: 28340041 [TBL] [Abstract][Full Text] [Related]
58. An intrathecally located broken catheter used for an intrathecal drug delivery system. Kim JH; Nahm FS; Chang JE; Park SY; Kim YC; Lee SC J Korean Med Sci; 2012 Oct; 27(10):1278-81. PubMed ID: 23091331 [TBL] [Abstract][Full Text] [Related]
59. Implantable drug delivery systems (IDDS) after failure of comprehensive medical management (CMM) can palliate symptoms in the most refractory cancer pain patients. Smith TJ; Coyne PJ J Palliat Med; 2005 Aug; 8(4):736-42. PubMed ID: 16128647 [TBL] [Abstract][Full Text] [Related]